Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.

Cramer, P

http://hdl.handle.net/10026.1/17909

10.1080/10428194.2017.1416364
Leukemia and Lymphoma
Taylor & Francis

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study


To link to this article: https://doi.org/10.1080/10428194.2017.1416364

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study


ABSTRACT
Health-related quality of life (HRQoL) is an important endpoint, especially in clinical trials for malignancies with a long course of disease, such as chronic lymphocytic leukemia (CLL). Patient-reported outcomes were examined in the randomized, double-blind, placebo-controlled HELIOS study to assess the impact of treatment with the Bruton’s tyrosine kinase inhibitor ibrutinib, added to bendamustine plus rituximab (BR) background therapy. Measures included FACIT-Fatigue, EORTC QLQ-C30, QLQ-CLL16, and EQ-5D-5L. Of 578 patients enrolled, 540 (93%) provided FACIT-Fatigue responses at baseline. Most had only a moderate degree of impairment at baseline; mean values did not appear to change over time in either treatment arm, suggesting that adding ibrutinib to BR did not impact health-related quality of life. However, post-hoc analyses showed that subgroups of patients with the worst fatigue, physical functional status, and well-being at baseline had greater improvements in these outcomes with ibrutinib plus BR treatment versus placebo.

Introduction
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults [1]. Early-stage disease is usually managed with a ‘watch-and-wait’ approach until it becomes symptomatic, with patients experiencing significant weight loss, fatigue, or fever; progressive bone marrow failure; or symptoms from lymphadenopathy, splenomegaly, or hepatomegaly [2,3]. Most conventional CLL therapies contain chemotherapeutic agents and may have toxic side effects and poor tolerability; particularly problematic because CLL primarily affects the elderly.

The disease-related symptoms, potential toxicity of therapy, and emotional and socioeconomic aspects of living with chronic illness can have profound effects on health-related quality of life (HRQoL) in patients with CLL [4–6]. As the median age at initial CLL diagnosis is 72 years, many patients face further challenges of managing comorbidities [7]. The most commonly reported symptom is fatigue [8], a multifaced phenomenon that reduces patients’ physical energy, mental capacities, and psychological alertness [8–10]. Approximately 9–25% of patients with CLL develop anemia, which can be caused by bone marrow infiltration, autoimmune phenomena, or chemoimmuno-therapy [5]. Anemia also contributes to fatigue and may cause shortness of breath and lethargy, further impairing physical functioning and HRQoL. Low-grade anemia (hemoglobin <12 g/dL) is often associated with significant reduction in HRQoL [5,11].

CONTACT Paula Cramer paula.cramer@uk-koeln.de Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group (DCLLSG), University Hospital of Cologne, Kerpener Str. 62, 50942 Cologne, Germany

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Ibrutinib is a first-in-class, oral, covalent inhibitor of Bruton’s tyrosine kinase, approved in the United States, Europe, and many other countries for treatment of CLL [12,13]. The HELIOS study, a large, international, double-blind, placebo-controlled phase 3 trial, demonstrated that the addition of continuous ibrutinib to up to six cycles of bendamustine plus rituximab (BR) significantly improved progression-free survival (PFS) compared with up to six cycles of BR alone in patients with relapsed/refractory CLL, with an 80% reduction in risk of disease progression or death [14]. Although 97% of patients experienced ≥1 adverse event (mostly mild/moderate in severity), no unexpected or cumulative toxicities occurred as the safety profile corresponded with toxicity rates previously reported for both BR chemoimmunotherapy and ibrutinib [15,16].

Increasing PFS and overall survival is the primary goal of current CLL treatments, but it is also important to maintain good HRQoL, as patients may live with their disease for many years. Furthermore, as antineoplastic therapies often have side effects, it is essential to understand the tradeoff between improvements in disease-related outcomes and any detrimental treatment-related impact on patients’ HRQoL. An understanding of patients’ symptoms, functioning, and overall well-being is valuable to clinicians, patients, and payers [6]. Patient-reported outcome (PRO) instruments are commonly used to assess patients’ overall experience in this regard [17], and are increasingly included as oncology trial endpoints to contextualize clinical endpoint findings and provide a more comprehensive picture of treatment effects [18–22].

To this end, it is imperative that PRO data in oncology trials are analyzed and reported in a meaningful way. Per regulatory guidelines, oncology trials tend to enroll patients who are expected to benefit from study treatment and are therefore not too ‘unwell’ [23]. Mean or median changes from baseline in the overall study population may not accurately reflect outcomes for smaller subgroups of patients with the worst baseline HRQoL. Importantly, patients with the greatest HRQoL impairment at baseline may be those most in need of a therapy that does not make them feel any worse.

Initial exploratory analyses in the HELIOS study indicated that, among patients with the worst baseline fatigue, there were apparent improvements in fatigue for both treatment groups in the first six cycles (i.e. while both groups were receiving BR), with significantly greater improvements among patients who continued ibrutinib versus placebo (p < .05 at Cycle 10) [14]. This analysis aims to further examine the HRQoL impact of ibrutinib treatment when added to BR background therapy for patients in the HELIOS study. Given that initial results suggested a positive treatment effect of ibrutinib plus BR in patients who were most fatigued at baseline, additional post-hoc analyses were performed to examine fatigue and other PROs (e.g. physical functioning, and general well-being), according to degree of baseline impairment.

**Materials and methods**

**Study design, patients, and treatment**

Full details of the HELIOS study design and methodology (NCT01611090) have been published previously [14]. Briefly, adults with CLL or small lymphocytic lymphoma requiring treatment according to International Workshop on Chronic Lymphocytic Leukemia criteria [3], and who had relapsed/refractory disease following ≥1 previous therapies, were enrolled across 133 sites (21 countries). An independent ethics committee or institutional review board approved the protocol at each site, and the study was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent.

Patients were randomized 1:1 to receive oral ibrutinib (420 mg daily) or placebo in addition to a background regimen of bendamustine (70 mg/m² on Days 2–3 in Cycle 1 and Days 1–2 in Cycles 2–6) plus rituximab (375 mg/m² on Day 1 of Cycle 1 and 500 mg/m² on Day 1 of Cycles 2–6) for up to six cycles with a duration of 28 days. After completion of six cycles, patients continued to receive ibrutinib or placebo in 28-day cycles until disease progression or unacceptable toxicity.

**PRO measures**

In the HELIOS study, PROs were implemented as secondary endpoints assessed by a prespecified analysis plan. PROs were collected using four standardized and widely accepted instruments for oncology: the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30, the EORTC QLQ-CLL 16 (a CLL-specific module), and the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) [4,24–28]. In addition to planned analyses on the domains/scales from each PRO instrument, post-hoc exploratory subgroup analyses were conducted using all four instruments to evaluate outcomes according to the degree of baseline impairment. Correlations between
fatigue levels, as measured by the FACIT-Fatigue scale, and hemoglobin levels indicating anemia (hemoglobin <11 g/dL) were also evaluated as part of the post-hoc exploratory analysis.

**Fatigue**

Fatigue was assessed using the FACIT-Fatigue scale, a 13-item instrument designed to specifically assess aspects of fatigue/tiredness in patients with cancer or other chronic diseases, including impact on daily activities and functioning [29]. Several studies of chronic diseases, including anemia and cancer [30–34], have shown the FACIT-Fatigue scale can be used to support valid inferences regarding patient fatigue. Items are scored on a 0–4 response scale (0 = not at all; 4 = very much), reverse scored where appropriate, and all items are summed to create a single fatigue score with a range from 0 to 52, where higher scores indicate better functioning or less fatigue. A change of ≥3 points is considered clinically meaningful [35].

**General cancer assessment, including physical functioning and well-being**

The EORTC QLQ-C30 is a 30-item general cancer assessment that incorporates five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), a global health-status and QoL scale (two items), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Scores range from 0 to 100 (for functional and global QoL scales, higher scores indicate a better level of functioning) [24]. In this analysis, the individual physical functioning domain was explored; a 10-point change was considered clinically meaningful [36].

The CLL-specific module QLQ-CLL16 was developed by the EORTC [37] and comprises 16 questions that address five domains of HRQoL important in CLL, including three multi-item scales (fatigue, treatment side effects and disease symptoms, and infections) and two single-item scales (social activities and future health worries) [4,28]. In this analysis, the individual QLQ-CLL16 item of feeling ill or unwell, which is measured on a 4-point scale (1 = not at all; 4 = very much), was assessed.

Generic measures of HRQoL and well-being were also collected using the EQ-SD-5L [38,39]. The EQ-SD-5L consists of a five-item descriptive system and the EuroQol visual analog scale (EQ-SD VAS) of self-rated health, with scores ranging from 0 to 100 (worst to best imaginable health state). Responses for the five dimensions are combined into a five-digit number describing respondents’ health state that can be converted into a single index value or utility score (using UK weights), ranging from −1 to 1, where lower scores indicate a worse health status.

**PRO instrument administration**

PRO instruments were administered to patients at the beginning of clinic visits to avoid bias from procedures or physician interactions. Data were collected using electronic data capture during double-blind treatment and post-treatment follow-up periods until disease progression, clinical cutoff, or death. The FACIT-Fatigue and EORTC QLQ-CLL16 instruments were administered on Day 1 of Cycles 1, 2, 4, and 6 (ibrutinib- or placebo-plus-BR treatment period), Cycles 8 and 10 (ibrutinib- or placebo-alone treatment period), at the end-of-treatment visit, and every 12 weeks during the post-treatment follow-up period. The EORTC QLQ-C30 and EQ-SD-5L instruments were administered on Day 1 of Cycles 1, 3, and 5 (ibrutinib- or placebo-plus-BR treatment period), Cycles 7 and 10 (ibrutinib- or placebo-alone treatment period), at the end-of-treatment visit, and every 12 weeks during the post-treatment follow-up period. Following disease progression, sites also attempted to administer the EQ-SD-5L every 16 weeks (up to three times) in person or via telephone [40].

**Statistical analyses**

PRO endpoints were analyzed for all patients in the intent-to-treat population who completed the FACIT-Fatigue instrument at baseline (Day 1 of Cycle 1) and had ≥1 post-baseline value.

The compliance rates of each PRO at each time point were calculated based on the sample size of each arm at baseline. Scores from FACIT-Fatigue, EORTC QLQ-C30, EORTC QLQ-CLL 16, and EQ-SD-5L were descriptively summarized by treatment group. Kaplan–Meier curves were generated for FACIT-Fatigue scores to estimate time to achieve a clinically meaningful change in each treatment group and were compared using a stratified log-rank test.

**Subgroup analyses**

Individual PROs were evaluated in a post-hoc subgroup analysis according to degree of HRQoL baseline impairment. The baseline score was defined as the score from Day 1, Cycle 1. For FACIT-Fatigue, EORTC QLQ-C30 Physical Functioning, and EQ-SD VAS scores, mixed-model analyses were implemented; patients were
stratified according to treatment group (ibrutinib/placebo) and baseline status on that PRO (dichotomized by most impaired quartile versus the other three quartiles). For the EORTC QLQ-CLL16 well-being item, patients were stratified according to treatment group and by whether they reported feeling ill/unwell ‘quite a bit’ or ‘very much’ at baseline, and for analysis of change over time, by the proportion of patients achieving a return to well-being (reported feeling ‘not at all’ ill/unwell). Mean differences from baseline at each time point between the two treatment arms were compared statistically using the mixed-effects model repeated measure (MMRM) method. This method was implemented using two stratification factors, treatment and status (worse/not worse), and included the interaction between treatment and status as covariates in the mixed model. The association between change in fatigue scores and hemoglobin levels was examined in patients in the highest (most fatigued) quartile of FACIT-Fatigue baseline scores using linear regression models.

Results
In total, 578 patients were randomized to ibrutinib plus BR or placebo plus BR in the HELIOS study (intent-to-treat population, n = 289 in each treatment group). Of these, 540 (93%) provided FACIT-Fatigue baseline responses and had ≥1 post-baseline value (PRO analysis population). Baseline demographic and clinical characteristics of patients who completed the FACIT-Fatigue instrument at baseline are shown in Table 1. Treatment groups were generally well balanced; however, a higher proportion of patients in the placebo group had Rai stage III/IV disease, hemoglobin levels indicative of anemia, and low platelet and absolute neutrophil counts, whereas the ibrutinib group had a higher proportion of patients with bulky disease and del11q.

Table 1. Demographics and clinical characteristics for patients who completed the FACIT-Fatigue instrument at baseline.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Ibrutinib + BR (n = 269)</th>
<th>Placebo + BR (n = 271)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), years</td>
<td>63.7 (9.69)</td>
<td>63.2 (9.36)</td>
</tr>
<tr>
<td>Sex, % male</td>
<td>67.7</td>
<td>65.7</td>
</tr>
<tr>
<td>ECOS status (grade 1), %</td>
<td>57.2</td>
<td>56.5</td>
</tr>
<tr>
<td>Advanced Rai stage (3–4), %</td>
<td>37.1 (88/237)</td>
<td>46.3 (112/242)</td>
</tr>
<tr>
<td>Bulky disease (≥5 cm), %</td>
<td>58.7</td>
<td>53.5</td>
</tr>
<tr>
<td>Del11q, %</td>
<td>29.4</td>
<td>23.2</td>
</tr>
<tr>
<td>Mutated IgVH, %</td>
<td>18.9</td>
<td>20.0</td>
</tr>
<tr>
<td>No. of prior therapies, median (range)</td>
<td>2.0 (1–11)</td>
<td>2.0 (1–9)</td>
</tr>
<tr>
<td>Hemoglobin ≤11 g/dL, %</td>
<td>26.8</td>
<td>33.6</td>
</tr>
<tr>
<td>Platelet count ≤100,000 µL, %</td>
<td>24.9</td>
<td>29.5</td>
</tr>
<tr>
<td>ANC ≤1500/µL, %</td>
<td>8.2</td>
<td>11.1</td>
</tr>
</tbody>
</table>

ANC: absolute neutrophil count; BR: bendamustine plus rituximab; Del11q: chromosome 11q deletion; ECOG: Eastern Cooperative Oncology Group; IgVH: immunoglobulin heavy-chain variable-region; SD: standard deviation.

Patient-reported outcomes
Baseline HRQoL scores were indicative of a moderate fatigue level and impaired functioning in the PRO analysis population: mean baseline FACIT-Fatigue score was 37.2 (standard deviation [SD] 10.4); mean EORTC-QLQ-C30 Physical Functioning score was 78.9 (SD 18.9); and mean EQ-SD-5L utility value was 0.79 (SD 0.18). On the EORTC QLQ-CLL 16 instrument, 16.7% of patients reported feeling ill ‘quite a bit’ or ‘very much’ at baseline.

Prespecified analyses in the overall analysis population
Overall compliance rates on the PRO instruments (FACIT-Fatigue, EORTC QLQ-C30, EORTC QLQ-CLL16, and EQ-SD-5L) were >90%, with <10% missing at most time points through Cycle 19.

The median time to improvement in FACIT-Fatigue score was not significantly different in the ibrutinib-plus-BR and placebo-plus-BR groups: 6.5 versus 4.6 months (hazard ratio 0.853; 95% confidence interval [CI]: 0.693–1.050). No changes from baseline over time were observed within or between treatment groups in mean summary scores on the FACIT-Fatigue scale, EORTC-QLQ-C30 subscales, EORTC-QLQ-CLL16 items, EQ-SD-5L utility value, or EQ-SD VAS. However, SDs were relatively large, and the data trended toward larger changes at the lower end of the scales, suggesting that data from a majority of patients with small changes may have masked larger changes in a minority of patients. Therefore, a subgroup analysis was undertaken, as described in Materials and methods, focusing on patients with the worst baseline PRO scores, who had the greatest potential for HRQoL improvement.

Subgroup analyses by degree of impairment at baseline
Among patients who were most fatigued at baseline, FACIT-Fatigue scores improved by several points following initiation of therapy in both treatment groups (Figure 1), but to a greater extent overall in the ibrutinib-plus-BR group (mean change +11.21) than in the placebo-plus-BR group (+8.57; mean difference 2.64 [95% CI: 0.396–4.879]; p = .0212).

Similarly, patients with the greatest impairment in baseline physical functioning (lowest quartile for EORTC-QLQ-C30 Physical Functioning score) demonstrated improvements in functional ability that were significantly greater with ibrutinib plus BR (mean
change (+18.7) than with placebo plus BR (+13.7; mean difference 5.0 [95% CI: 0.75–9.25]; \( p = .0211 \) (Figure 2). Patients in the upper three quartiles (i.e. least impairment in baseline physical functioning) showed little mean change over time.

EQ-5D VAS scores (self-rated health status) also showed improvement over time in the patient quartile with the lowest baseline scores; this improvement was not detected in the upper three quartiles, although the magnitude of improvement in the lowest quartile did not differ significantly between treatment groups (mean change +19.1 versus +20.7, respectively; \( p = .5088 \)).

In the 90 patients who reported that they felt ill ‘quite a bit’ or ‘very much’ at baseline, approximately 20–30% achieved a return to well-being (reported feeling ‘not at all’ ill/unwell) by the first visit following treatment initiation. The proportion of patients achieving a return to well-being after Cycle 6 (i.e. after the end of BR background therapy) increased with time on treatment, to a greater extent in the ibrutinib-plus-BR group than in the placebo-plus-BR group (Figure 3).

**Association between fatigue and hemoglobin levels**

In the HELIOS study, an initial decrease in mean hemoglobin levels, followed by increasing levels after treatment Cycles 2–3, was observed in both the ibrutinib-plus-BR and placebo-plus-BR groups [14]. In the subgroup of patients with the worst baseline fatigue, changes in hemoglobin levels were consistent with those in the overall patient population, and increased in alignment with improvements in FACIT-Fatigue scores (Figure 4). Linear regression analysis of the association between hemoglobin levels and fatigue in this patient subgroup demonstrated that, during the first six treatment cycles, when fatigue improved at the greatest rate, changes in hemoglobin from the previous cycle significantly predicted concurrent changes in fatigue in the ibrutinib-plus-BR treatment group (baseline to Cycle 2 \( r = 0.26 \); Cycle 2 to Cycle 4 \( r = 0.37 \), and Cycle 4 to Cycle 6 \( r = 0.33 \); \( p < .05 \) for all) (Figure 5).

**Discussion**

The current analysis examined PROs in the HELIOS study to assess patient well-being and the impact of treatment with ibrutinib on HRQoL when added to BR background therapy. In the primary analysis, the addition of ibrutinib significantly improved PFS and overall response rate without unexpected or cumulative toxicities, compared with placebo plus BR in patients with relapsed/refractory CLL [14]. Consistent with the study entry criteria and the fact that BR was given as background therapy, all patients were deemed suitable
for chemoimmunotherapy. This PRO data analysis showed that most patients entered the trial with only a moderate degree of fatigue and HRQoL impairment at baseline, and mean values did not appear to change over time in either arm. These data indicate that in the overall patient population there was either no room for improvement or the addition of ibrutinib did not improve nor adversely impact HRQoL, thus supporting a favorable benefit-risk ratio of ibrutinib. Similar findings were recently reported for the COMPLEMENT 2 phase 3 trial of patients with relapsed CLL, which assessed HRQoL outcomes with the addition of ofatumumab to fludarabine plus cyclophosphamide. PRO improvements were not significantly different between treatment arms for global health status/HRQoL \( (p = 0.7278) \) or B symptoms \( (p = 0.5968) \), suggesting that addition of ofatumumab did not have a negative impact \[41\].

However, post-hoc analysis of HELIOS data revealed that among the subgroup of patients with the worst fatigue, functional status, and well-being at baseline, greater improvements were achieved with ibrutinib plus BR. Improvements in fatigue paralleled increases in hemoglobin levels observed in both treatment groups (most rapidly during the BR treatment cycles). Linear regression analysis of the relationship between changes in hemoglobin level and fatigue score (for patients in the lowest quartile for baseline fatigue, regardless of treatment group) confirmed that an increase in hemoglobin was predictive of fatigue score improvement.

Because oncology trials tend to enroll patients who are well enough to benefit from treatment (per regulatory requirements), the effects of treatment on HRQoL...
may be smaller than if sicker patients are enrolled [20]. This analysis demonstrates how significant improvements achieved in a proportion of patients may have been masked in the evaluation of PROs based on mean changes in the whole patient population. This supports our approach of stratifying patients into quartiles for analysis of PROs in a population with variable potential for overall improvement. In smaller samples, it may be appropriate to stratify patients above/below the median PRO score. Although there are some limitations to this approach (e.g. appropriate stratification cutoffs may vary between patient populations and differ for PRO measures), examining PRO data in specific subgroups rather than for the whole population may be a more patient-centered approach that helps to more fully elucidate the patient experience. Furthermore, re-evaluation of inclusion criteria in oncology trials to enroll sicker patients may provide more representative insight into treatment effects on ‘real-world’ patients [23].

It is important to note that the data should be interpreted with caution. The subgroups of patients with the worst fatigue or physical impairment at baseline were relatively small. Overall, the number of patients with available data decreased during the follow-up period; hence, the number of patients included...
in the analyses after Cycle 19 is low. The remaining patients may represent those who responded better to treatment, or are in remission (patients who progressed/discontinued are more likely to have dropped out), which may introduce potential bias toward patients with better HRQoL scores and longer follow-up. Although the data suggest that addition of ibrutinib to BR background therapy had no impact on patients’ HRQoL in the PRO population, it cannot be concluded that this remains true after a longer treatment period (e.g. 2 years). Nevertheless, the safety profile of ibrutinib combined with BR in the HELIOS study was similar to that of the individual regimens and there were no unexpected safety signals; as the observed side effects were not cumulative [14], HRQoL would not be expected to be detrimentally affected by drug-related toxicities with ibrutinib added to BR.

Another limitation to interpretation of this analysis is that the HELIOS study was not designed to evaluate ibrutinib as a single agent or with rituximab versus ibrutinib plus BR. This analysis suggests that fatigue, physical functioning, and well-being were improved with the addition of ibrutinib to BR in the worst-affected patients, in addition to overall improvements in the quality and duration of treatment response. However, the question remains whether the BR backbone is necessary to achieve these improvements in this population of relapsed/refractory patients, or alternatively, whether BR dampens the HRQoL benefits of ibrutinib when given in combination.

Although data are limited, the positive impact of ibrutinib treatment on HRQoL has been reported in other trials. In a single-arm phase 2 study of ibrutinib plus rituximab for high-risk CLL, patients showed significant improvements in global health status, functioning, and symptom scales on the EORTC-QLQ-C30 at 12 months [42]. In the phase 3 RAY (MCL3001) trial of patients with relapsed/refractory mantle cell lymphoma, ibrutinib monotherapy was associated with improved Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) subscale and total scores, as well as EQ-5D-5L utility and EQ-5D VAS scores, compared with temsirolimus [43].

In conclusion, the results of this post-hoc analysis of the HELIOS study highlight that, although most patients had relatively good baseline HRQoL scores, patients with greater impairments or worse HRQoL cannot be overlooked, as they in particular require therapies that are well tolerated and do not further impair their HRQoL. In the HELIOS study, ibrutinib treatment added to a background BR regimen not only improved PFS and duration of treatment response in the overall study population, but also improved fatigue, physical functioning, and well-being in CLL patients with the greatest baseline deficits in these HRQoL domains. These findings emphasize the need for therapies that are both efficient and well tolerated for patients with poor functional status related to CLL.
**Acknowledgements**

This study was funded by Janssen Research & Development. We thank the patients who participated in this trial and their families, and the global study investigators and study staff at each of the clinical sites. The authors would like to thank RJ Wirth and Jim McGinley from Vector Psychometric Group for conducting the linear regression analysis, Charles Phelps and Pushpika Thilakaratne of Janssen for providing statistical support, and Chiu-Fang Chiou and Jay Trudeau of Janssen for their critical review of the manuscript.

**Potential conflict of interest:** Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1416364

**Funding**

Writing assistance was provided by Jean Turner and Safeer Mughal of PAREXEL, and was funded by Janssen Global Services.

PC has received research grants from Gilead, GlaxoSmithKline, F. Hoffmann-La Roche, Janssen-Cilag, and Novartis; honoraria for scientific talks from F. Hoffmann-La Roche and Janssen-Cilag; honoraria for advisory boards from AbbVie, AstraZeneca, Janssen-Cilag and Novartis; and travel grant support from Astellas, Gilead, F. Hoffmann-La Roche, Janssen-Cilag, and Mundipharma. GF has received grants and personal fees from Celgene and Janssen; and personal fees from Abbvie and Lundbeck. M-SD has received personal fees and non-financial support from Abbvie, Gilead, and Janssen. JL has received fees for speaker bureaus and advisory boards from Abbvie, Gilead, and Janssen. JR has received grants and personal fees from Janssen and Pharmacyclics. AG has received fees for speaker bureaus and advisory boards from Johnson & Johnson/Pharmacyclics and Takeda; consultancy and advisory board fees from Celgene; research support and consultancy fees from Genentech; and honoraria from Acerta. ST, EKHC, NS, MM, MS, and AH are employees of Janssen. JD is an employee and equity owner of Janssen. RS-S, SG, AJ, and AC-K declare no conflicts of interest.

**References**


[12] Imbruvica [prescribing information]. Sunnyvale, CA, USA: Pharmacies LLC; 2016. [Internet]; Available from: https://www.imbruvica.com/prescribing-information


